Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology
Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
IJMS | Free Full-Text | Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
Winner of 3-way war among CDK-inhibitor breast cancer drugs will come out in 5 years' < Pharma < Article - KBR
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology
Efficacy of KISQALI® (ribociclib) + AI in 1L Postmenopausal | HCP
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
MONALEESA-7 Shows Overall Survival Benefit for Ribociclib/Endocrine Therapy - The ASCO Post
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7) - Nadia Harbeck ...
Dr Sunil Verma on Twitter: "Monaleesa 7 results by @DrDebuTripathy - first line Ribociclib in pre/peri-menopausal HR+ve MBC. Improved PFS (HR 0.55) #SABCS17 https://t.co/rOYQSEEH7C" / X
PDF) Updated Overall Survival of Ribociclib Plus Endocrine Therapy vs Endocrine Therapy Alone in Pre- and Perimenopausal Patients With HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer - Medical Conferences
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer - ScienceDirect
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer | npj Breast Cancer
Efficacy Across Trials | KISQALI® (ribociclib) | HCP
Novel Drugs in Advanced Breast Cancer: Improving Patient Outcomes - ppt download
2021 Update on Systemic Therapy for Breast Cancer | Published in healthbook TIMES Oncology Hematology
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer | NEJM
Download Poster: Overall Survival with Kisqali® plus Endocrine Therapy in Patients with Advanced Breast Cancer with Visceral Metastases 6
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect
Dr Sunil Verma on Twitter: "Monaleesa 7 results by @DrDebuTripathy - first line Ribociclib in pre/peri-menopausal HR+ve MBC. Improved PFS (HR 0.55) #SABCS17 https://t.co/rOYQSEEH7C" / X
Kisqali extends survival by 1 year in advanced breast cancer < Pharma < Article - KBR
Efficacy Across Trials | KISQALI® (ribociclib) | HCP
Efficacy of KISQALI® (ribociclib) + AI in 1L Premenopausal | HCP
Asco 2019 – Novartis looks to premenopausal survival to reinvigorate Kisqali | Evaluate
